We first explored the role of ATM mutations in bladder cancer by evaluating the associations between the gene mutation status and clinical phenotypes in the immunotherapy cohort and TCGA-Bladder cancer cohort. This evidence concerns the gene ATM and urinary bladder carcinoma.